Research and Markets: Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012 Features Players BioStar Pharmaceuticals, Inc., Yuhan Corporation and Rigel Pharmaceuticals, Inc.

Research and Markets has announced the addition of Global Markets Direct's new report "Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012" to their offering.

“Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012”

Global Markets Direct's, 'Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Inflammatory Disorders, complete with latest updates, and special features on late-stage and discontinued projects. Buy Feldene (Piroxicam) pills online without prescription It also reviews key players involved in the therapeutic development for Respiratory Tract Inflammatory Disorders. Respiratory Tract Inflammatory Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Respiratory Tract Inflammatory Disorders.
- A review of the Respiratory Tract Inflammatory Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Tract Inflammatory Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Mentioned:
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
AstraZeneca PLC
MedImmune LLC
Novartis AG
ALK-Abello A/S
Rigel Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Limited
Orchid Chemicals & Pharmaceuticals Ltd
Pharmaxis Ltd.
Yuhan Corporation
Cytos Biotechnology AG
Allergopharma Joachim Ganzer KG
Mucosis B.V.
Funxional Therapeutics Ltd
Oxagen Limited
Pulmatrix, Inc.
AIM Therapeutics Inc.
aRigen Pharmaceuticals, Inc.
BioStar Pharmaceuticals, Inc.
BaroFold, Inc.
iNova Pharmaceuticals (Australia) Pty Limited
Endacea, Inc.
Pierre Fabre Medicament
Asmacure Limited